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Abstract
Recent studies demonstrated that cancer stem cells (CSCs) have higher tumorigenesis properties than those of
differentiated cancer cells and that transcriptional factor-SOX2 plays a vital role in maintaining the unique properties of
CSCs; however, the function and underlying mechanism of SOX2 in carcinogenesis of lung cancer are still elusive. This study
applied immunohistochemistry to analyze the expression of SOX2 in human lung tissues of normal individuals as well as
patients with adenocarcinoma, squamous cell carcinoma, and large cell and small cell carcinoma and demonstrated specific
overexpression of SOX2 in all types of lung cancer tissues. This finding supports the notion that SOX2 contributes to the
tumorigenesis of lung cancer cells and can be used as a diagnostic probe. In addition, obviously higher expression of
oncogenes c-MYC, WNT1, WNT2, and NOTCH1 was detected in side population (SP) cells than in non-side population (NSP)
cells of human lung adenocarcinoma cell line-A549, revealing a possible mechanism for the tenacious tumorigenic potential
of CSCs. To further elucidate the function of SOX2 in tumorigenesis of cancer cells, A549 cells were established with
expression of luciferase and doxycycline-inducible shRNA targeting SOX2. We found silencing of SOX2 gene reduces the
tumorigenic property of A549 cells with attenuated expression of c-MYC, WNT1, WNT2, and NOTCH1 in xenografted NOD/
SCID mice. By using the RNA-Seq method, an additional 246 target cancer genes of SOX2 were revealed. These results
present evidence that SOX2 may regulate the expression of oncogenes in CSCs to promote the development of human lung
cancer.
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Introduction
Cancer stem cells (CSCs) represent a very small population of
cancer cells from which tumors originates. They possess the same
unique character as embryonic stem (ES) cells, such as
clonogenicity, pluripotency and self-renewal and thus have the
ability to initiate a tumor, sustain its growth and be responsible for
cancer recurrence [1]. Recent studies have shown that CSCs like
cell subpopulations could be isolated from various cultured tumor
cell lines or tissues by using the Hoechst33342 dye efflux method
to separate side population (SP) cells [2] or by sorting cells
expressing specific stem cell surface markers, such as CD133(+),
CD44(+), CD34(+) and CD38(+) [3–5] et al.
Lung cancer represents the most common cause of cancer-
related lethality in both men and women throughout the world
with very low five-year survival rates, even after clinical therapy
[6,7]. This malignancy is usually divided into different histological
types according to the phenotypes of cells from which the tumor
arises, including squamous cell carcinoma (SCC), adenocarcinoma
and neuroendocrine carcinoma, such as small cell lung cancer
(SCLC) as well as large cell lung cancer [8]. Adenocarcinoma,
SCC and large cell lung cancer are also collectively named non-
small cell lung cancer (NSCLC), representing the most common
types of lung cancer with lower growth rate and spread speed than
those of SCLC. Among NSCLC, peripheral adenocarcinoma is
the leading subtype which accounts for approximately 80% of
cases in lung cancer patients [9]. Several studies showed that
CD133 (+), CD44 (+) and CD87 (+) can be used as surface markers
to identify CSCs in lung cancer [10–12]. Recent studies reported
isolated SP from both a mouse tumor model [13] and a variety of
lung cancer cell lines by using the Hoechst dye efflux method [14–
16]. It was found that isolated SP cells show higher expression
levels of stem cell genes, such as SOX2 and OCT4 and
tumorigenesis properties than NSP cells [2].
The important function of transcription factor SOX2 in
maintaining the unique properties of ES cells and CSCs has been
extensively investigated. It was also established that induced
pluripotent stem (iPS) or pluripotent cancer (iPC) cells could be
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tion factors such as Oct4, Klf4 and c-Myc into fibroblast or cancer
cells [17–20]. In fact, SOX2 was highly expressed in isolated CSCs
like cells at both mRNA and protein levels. Extensive studies
revealed that SOX2 regulates the complex transcriptional network
to maintain the unique characteristics of stem cells [21] and the
anti-apoptosis property of CSCs [15,22]. Consequently, targeting
of SOX2 is a promising strategy for tumor therapy. Although
numerous investigations of clinically-derived tumor tissues report-
ed the specific overexpression of SOX2 in certain types of tumor
tissues, such as prostate and breast cancers [22,23] and indicated
its importance for tumorigenesis, the underlying mechanism for
the tumorigenic property of SOX2 gene is still largely unknown.
Oncogenes play important roles in the development of
carcinoma. Among them, NOTCH, WNT and c-MYC are well-
established oncogenes in the initiation and progression of lung
cancer cells. It was reported that WNT family proteins-WNT1,
WNT2 and NOTCH proteins -NOTCH1, NOTCH3 as well as
their downstream protein HES-1 are overexpressed in NSCLC
cell lines or tissues [24–31]. Overexpression of these oncogenes or
activation of their signal pathways induced lung carcinoma
[32,33]. As such, targeting of these genes by using siRNA/
shRNA, mutation, specific inhibitors or monoclonal antibodies
could inhibit tumor growth and induce apoptosis in lung cancer
cell lines in experimental mouse models [4,34–36]. Aside from
their important role in tumorigenesis of lung cancer, these
oncogenes also formed a functional interaction network. It was
also reported that NOTCH1 induces the expression of c-MYC, in
addition, both proteins regulate the expression of same target
genes participating in cell growth regulation [37]. c-MYC was also
revealed to be the downstream target of WNT/b-Catenin
signaling and further studies showed the promoter of c-MYC to
align with WNT/b-Catenin responsive enhancers [38], revealing a
possible regulatory mechanism of WNT signaling on c-MYC.
In view of the important contributions of SOX2 in maintaining
the stemness property of CSCs, we hypothesize that SOX2 might
govern the transcriptional network of oncogenes to affect the
tumorigenesis of lung carcinoma. Our results thus far demonstrate
that SOX2 regulates the transcriptional network of oncogenes,
including WNT1, WNT2, NOTCH1 and c-MYC and promotes the
tumorigenesis of human lung cancer cells. This study also supports
the notions that targeting of SOX2 is an effective strategy for lung
cancer therapy.
Materials and Methods
Ethics Statement
All animal experiments were performed strictly under the
guidelines on laboratory animals of Nankai University and were
approved by the Institute Research Ethics Committee at the
Nankai University (Permit number: 10011). Mice were anesthe-
tized with a mixture of oxygen/isoflurane before each experiment
and all efforts were made to minimize their suffering. For human
samples, the commercialized high-density tissue microarrays were
purchased and the use of the human tissue in this study was
approved by the Human Research Committee of Nankai
University.
Vector Construction
shRNA sequence for silencing human SOX2 gene was searched
and blasted using RNAi designer from the invitrogen website
(https://rnaidesigner.invitrogen.com/rnaiexpress/index.jsp). One
shRNA targeting human SOX2 was designed and chemically
synthesized as shRNA-SOX2 (AAAAGGGACATGAT CAG-
CATGTATTGGATCCAATACATGCTGATCATGTCCC),
and a scrambled sequence (AAAAGCTACACTATCGAG-
CAATTTTGGATCCAAAATTGCTCGATAGTGTAGC) was
used as control for knockdown analysis. The palindromic DNA
oligos were annealed to each other to form a double-strand oligo
and ligated to the linearized pLV-H1TetO-GFP-Bsd (Cat#
SORT-C03, Biosettia Inc., San Diego, CA) and pLV-H1-EF1a-
puro (Cat# SORT-B19, Biosettia Inc., San Diego, CA) vector to
generate circled pLV-H1TetO-shRNA-SOX2-GFP-Bsd and
pLV-H1-EF1a-shRNA-SOX2-puro plasmid separately. The pu-
romycin resistant cDNA from pLV-H1-EF1a-shRNA-SOX2-puro
plasmid was cut by Nhe I and Sal I enzyme to replace the GFP-
Bsd fragment in pLV-H1TetO-shRNA-SOX2-GFP-Bsd to gen-
erate the pLV-H1TetO-shRNA-SOX2-puro plasmid.
Cell Culture
Wild types (Wt) of A549 and H460 cells were obtained from
ATCC. A549-Wt cells were infected with lentivirus encoding the
firefly luciferase (FL) gene (Cat. # GlowCell-14b-1, Biosettia,
SanDiego, CA) and selected by 10 mg/ml Blasticidin (Bsd) to
generate A549 cells with stable overexpression of FL (A549-FL).
A549-Wt, H460-Wt and A549-FL cells were infected with
lentivirus carrying pLV-H1TetO-shRNA-SOX2-puro plasmid
(Biosettia, SanDiego, CA), followed by clonal selection using
puromycin (10 mg/ml for A549 and 2 mg/ml for H460) to
generate a polyclone of A549, H460 or A549-FL cells with stable
expression of Dox inducible shRNA-SOX2 (A549-H1tetO-
shRNA-SOX2, H460-H1tetO-shRNA-SOX2 or A549-FL/
H1tetO-shRNA-SOX2). A549 and H460 cells were maintained
in F12K and RPMI 1640 media supplemented with 10% fetal
bovine serum in the presence of 100 u/ml penicillin and 0.1 mg/
ml streptomycin separately. For control purposes, A549-Wt,
H460-Wt and A549-FL were infected with lentivirus carrying
scrambled shRNA and subjected to identical clone selection
procedures to generate the stable control cell lines A549-H1tetO-
shRNA-Con, H460-H1tetO-shRNA-Con and A549-FL/H1tetO-
shRNA-Con.
Immunohistochemistry and Tissue Microarrays
The expression of SOX2 in high-density tissue microarrays
(Cat. # BC04119b, LC727, LC2085b, LC2161, Alenabio, Xi’an,
China PR) was detected by the standard biotin-avidin-complex
method with monoclonal mouse antibody against SOX2 (Cat. #
ab75485, Abcam Inc, Cambridge, UK) at a 1:200 dilution. The
images were recorded by Olympus BX51 Epi-fluorescent micros-
copy under a 106or 406objective (Olympus Co. Tokyo, Japan).
Flow Cytometry Analysis and Sorting
A549-Wt cells were harvested and resuspended in pre-warmed
DMEM+ buffer (DMEM with 2% FBS and 10 mM HEPES
buffer) at a density of 1.0610
6 cells/ml. Hoechst 33342 dye was
added at a final concentration of 10 mg/ml in the presence or
absence of 10 mM Fumitremorgin C (FTC). Cell samples were
placed in a 37uC water bath for 60 minutes (min) and mixed every
10 min. Cells were collected and resuspended in cold HBSS+
buffer (Hanks’ Balanced Salt Solution with 2% FBS and 10 mM
HEPES buffer). At the end of the staining period, cells were
resuspended in cold HBSS+ buffer containing 2 mg/ml propidium
iodide (PI) for dead cell discrimination. The Hoechst dye was
excited with a UV laser at 355 nm, and its fluorescence measured
with a 460/50 BP filter (Hoechst Blue) and a 670/30 BP filter
(Hoechst Red).
SOX2 in Lung Cancer
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Total mRNAs from A549 cells were isolated by TRIzol reagent
(Cat. #15596-018, Invitrogen Inc, Carlsbad, CA) and reverse-
transcribed into cDNAs with MMLV reverse transcriptase
(Promega, Madison, MI). Following this, semi-quantitive RT-
PCR was performed to detect the mRNA expression levels of
NOTCH1, WNT1, WNT2, c-MYC, SOX2, OCT4, NANOG, ABCB1
and ABCG2. For an equal loading control, mRNA of human b-
actin was tested at the same time. Primers used for both
experiments are summarized in Table 1. Real time RT-PCR
was performed on Opticon (Bio-Rad, Hercules, CA) in 25 ml
reaction volumes by using TransStart Green qPCR SuperMix Kit
(TransGen Biotech, Beijing, China, PR). The 2
2DDCt method was
used to determine the relative mRNA folding changes. Statistical
results were averaged from three independent experiments
performed in triplicate.
Western Blotting
Cell lysates from A549 and H460 cell lines were prepared with
RIPA buffer in the presence of protease inhibitor cocktails as
described previously [22]. Protein (20 mg) was loaded onto 5–12%
Tris-Acrylamide gels and blotted with antibodies that included:
polyclonal anti-SOX2, WNT2 (Cat.# sc-20088, sc-50361, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), WNT1 (Cat.#
ab85060, Abcam Inc, Cambridge, UK), monoclonal anti-
NOTCH1 (Cat.# 3608, Cell Signal Technology Inc, Danvers,
MA), c-MYC, b-actin (Cat.# sc-40, sc-47778, Santa Cruz
Biotechnology, Inc. Santa Cruz, CA), and horseradish peroxi-
dase-conjugated secondary antibodies. Blotting results were
detected by an ECL chemiluminescence kit (Millipore, Billerica,
MA).
Tumor Xenograft
Male NOD/SCID mice at 6–8 weeks age were separated
randomly into two groups (n=5 for each group). 1610
6 A549-FL/
H1tetO-shRNA-Con or A549-FL/H1tetO-shRNA-SOX2 cells
were xenografted into each mouse through tail vein injection. All
mice were fed with 0.2 mg/ml Dox plus 0.05% sucrose in the
drinking water from the first day after inoculation.
Bioluminescent Image
Mice were anesthetized with a mixture of oxygen/isoflurane
and received luciferin (Cat. # 119222, Caliper Life Sciences,
Hopkinton, MA) i.p at 150 mg/g body weight. Bioluminescent
signals were measured 10 min later with an IVIS 100 imaging
system and quantified with Living Image Software (Xenogen,
Alameda, CA).
RNA-Seq
The A549-H1tetO-shRNA-SOX2 and its control cells were
collected after being incubated with Dox for 4 days. 4 mg total
Table 1. The primers used for RT-PCR and real-time RT-PCR.
WNT1 Forward primer 59- CCCGGTTATTCGCCCACCCG -39
Backward primer 59- CAAGGGGTCTCCCGCGGAGA -39
WNT2 Forward primer 59- ACAGCAGGCCGTGTGTGCAA -39
Backward primer 59- AGGCAGTCCTGACAGCGCAC -39
NOTCH1 Forward primer 59- CGTCCGTGCCCCTCAACCAC -39
Backward primer 59- CAGGACGGTGCTGGTGCCAG -39
c-MYC Forward primer 59- CGCCCTCCTACGTTGCGGTC -39
Backward primer 59- CGTCGTCCGGGTCGCAGATG -39
SOX2 Forward primer 59- AAAACAGCCCGGACCGCGTC -39
Backward primer 59- CTCGTCGATGAACGGCCGCT -39
NANOG Forward primer 59- ACCTCAGCCTCCAGCAGATGCA -39
Backward primer 59- GGTGCTGAGGCCTTCTGCGT -39
OCT4 Forward primer 59- AAGCGATCAAGCAGCC -39
Backward primer 59- GGAAAGGGACCGAGGAGTA -39
ABCB1 Forward primer 59- TTGAAGGGGACCGCAATGGAGGA -39
Backward primer 59- GTCCAGCCCCATGGATGATGGC -39
ABCG2 Forward primer 59- CACCAATGGCTTCCCCGCGAC -39
Backward primer 59- GGGTCCCAGGATGGCGTTGAGA -39
b-actin Forward primer 59- GGCATCCACGAAACTACCTT -39
Backward primer 59- CTCGTCATACTCCTGCTTGC -39
doi:10.1371/journal.pone.0036326.t001
Table 2. The correlation of SOX2 with clinical status of
patient with lung cancer.
SOX2 (+) cell counts #10% 11–30% 31–49% $50% p Value
Tumorigenesis ,0.001
Normal/Paracarcinoma 31 6 1 0
Tumor 9 42 82 284
Adenocarcinoma 42 54 41 2 7
SCC 01 53 11 0 4
Large cell carcinoma 31 5 2 2
SCLC 21 2 3 1
Gender 0.322
Male 32 35 66 201
Female 8 13 17 83
Age at diagnosis 0.024
,65 9 33 50 207
$65 0 9 32 77
Histological phenotype 0.011
NSCLC 7 41 80 253
SCLC 2 1 2 31
TNM stage
NSCLC 0.705
I-II 73 46 01 8 2
III-IV0 5 1 0 3 3
SCLC 0.327
I-II 10 1 2 0
III-IV0 1 1 7
Histological grade
Adenocarcinoma 0.002
Grade 1 2 11 11 15
Grade 2 1 6 16 54
Grade 3 1 4 13 50
Localization of SOX2 ,0.001
Cytoplasma 40 19 26 53
Nuclear + Cytoplasma 0 29 57 231
doi:10.1371/journal.pone.0036326.t002
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# Pathway
Count of DEG with pathway
annotation Pvalue
1 Ribosome 27 8.18E-09
2 Aminoacyl-tRNA biosynthesis 14 8.31E-06
3 Protein processing in endoplasmic reticulum 24 0.00067961
4 Renal cell carcinoma 15 0.00114849
5 Metabolic pathways 129 0.00132165
6 Bladder cancer 11 0.0027594
7 Insulin signaling pathway 23 0.0031735
8 Vibrio cholerae infection 12 0.00394879
9 Gap junction 16 0.00487479
10 Pathways in cancer 45 0.00773737
11 Lysosome 20 0.00824269
12 Glycosaminoglycan biosynthesis - keratan sulfate 5 0.00859688
13 Protein export 6 0.00925981
14 Vasopressin-regulated water reabsorption 9 0.01188259
15 Arginine and proline metabolism 10 0.01337271
16 DNA replication 8 0.01393426
17 Shigellosis 12 0.01882112
18 Phosphatidylinositol signaling system 13 0.01897797
19 Glycerolipid metabolism 8 0.0191644
20 Alanine, aspartate and glutamate metabolism 7 0.01921653
DEG: differentially expressed genes.
doi:10.1371/journal.pone.0036326.t003
Figure 1. Immunohistochemical staining of SOX2 (brown) in human lung tissue of normal individuals, and patients with squamous
lung carcinoma, adenocarcinoma lung cancer, small cell lung cancer and large cell lung cancer in paraffin-embedded human lung
cancer tissue microarray. The representative staining of SOX2 in these tissues was subjected separately to microscopy images under 106(A) and
406objective (B).
doi:10.1371/journal.pone.0036326.g001
SOX2 in Lung Cancer
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36326Figure 2. Oncogenes WNT1, WNT2, c-MYC and NOTCH1 are specifically overexpressed in SP of human lung adenocarcinoma cell line
A549. A. SP cells in A549 were detected and separated by FACS using the Hoechst33342 dye efflux method (left) and verified by their failure to efflux
this dye after incubation with FTC, a specific inhibitor of multidrug transporter-ABCG2 (right). This figure represents 1 of 3 experiments. The mRNA
expression levels of oncogenes and stem cell genes were compared between the SP and NSP cells by using semi-quantitive RT-PCR, real-time RT-PCR
in B and C separately, n=3. D. Western blotting results of WNT1, WNT2, NOTCH1, c-MYC and SOX2 proteins in SP and NSP of A549 cells.
doi:10.1371/journal.pone.0036326.g002
SOX2 in Lung Cancer
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36326Figure 3. SOX2 regulates the expression of oncogenes in both A549 and H460 cells. A. A549-H1tetO-shRNA-SOX2 and control cells were
incubated with Dox for 4 days and silencing of SOX2 gene was confirmed by Western blotting. B. FACS analysis of the SP in A549 cells with or without
SOX2 silencing. The SP cells in A549 were confirmed by their ability to efflux Hoechst 33342 dye in the absence of FTC (up panel, FTC-), but fail to
efflux the dye after incubation with FTC (low panel, FTC+). C. The percentage of SP in A549 cells from each experiment group was averaged from
three independent experiments and plotted. D. Real-time RT-PCR was used to compare mRNA expression levels of oncogenes in A549 cell line with
SOX2 in Lung Cancer
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Oligo(dT) magnetic beads adsorption method was used to purify
mRNA, their transcriptome data were profiled and compared
following standard protocols (digital gene expression, DGE, 3
million reads, Beijing Genomics Institute at Shenzhen, China).
The cancer genes were selected from 7 databases summarized in
the website: http://microb230.med.upenn.edu/protocols/
cancergenes.html and those genes with false discovery rate
(FDR) ,0.001 were selected out as the target genes of SOX2.
RNA-Seq data have been deposited to NCBI Gene Expression
Omnibus (GEO) database (GSE36597; reviewer access link:
http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=druvhickewcwcvy&acc=GSE36597).
Statistical Analysis
Values were expressed as Means 6 S.E.M. Significance was
determined by x
2 test in Table 2 and hypergeometric test in
Table 3, others were determined by Student’s t-test. A value of
p,0.05 was used as the criterion for statistical significance. *
indicates significant difference with p,0.05, ** indicates significant
difference with p,0.01.
Results
SOX2 is Specifically Expressed in Human Lung Cancer
Tissues
To determine whether SOX2 contributes to tumorigenesis of
lung cancer, an immunohistochemical method was used to detect
expression of SOX2 in human lung tissues of normal/paracarci-
noma (n=38), adenocarcinoma (n=200), SCC (n=150), SCLC
(n=36) and large cell lung cancer (n=31). The correlation of
SOX2 with clinical status of patients with lung cancer was
summarized in Table 2. Predominantly higher expression of
SOX2 was found in both NSCLC and SCLC than in normal/
paracarcinoma tissues (p,0.001), indicating the important role of
SOX2 in the tumorigenesis of lung cancer. Statistically results
significant showed the number of SOX2 positive cells to be
positively correlated with age at diagnosis (p=0.024). Moreover,
SCLC tissues revealed a higher expression level of SOX2 than
NSCLC tissues (p=0.011). There was a positive correlation
between SOX2 and the pathological degree of human adenocar-
cinoma (p=0.002), indicating that SOX2 may inhibit the
differentiation of adenocarcinoma cells. From results of immuno-
histochemical staining (Fig. 1), we found either cytosol or both
nuclei and cytosol localization of SOX2 in cancer cells, which was
consistent with our previous findings in human prostate cancer
cells [22]. In addition, most of the tumor tissues with high
expression level of SOX2 showed both nuclear and cytosol
localization of SOX2; in contrast, those tissue with lower
expression level of SOX2 always revealed only cytosol localization.
The correlation between SOX2 expression level and its localiza-
tion was significant (p,0.001); however, there was no statistically
significant relationship between SOX2 positive cancer cell counts
and TNM stages or gender.
Oncogenes WNT1, WNT2, NOTCH1 and c-MYC are
Overexpressed at Both mRNA and Protein Levels in SP
Cells of the A549 Cell Line
Following identification of specific overexpression of SOX2 in
human lung tumor tissues, the expression of SOX2 and well-
established oncogenes were compared between SP and none side
population (NSP) in A549 cells. SP cells are CSCs-like cells that
show higher tumorigenesis and chemo-resistant properties than
those of NSP cells [39,40]. Since they express high expression
levels of ATP-binding cassette (ABC) transporter family members,
which help them to extrude the Hoechst 33342 dye and some
drugs more effectively, SP cells could be isolated by the Hoechst
33342 efflux method using FACS. As shown in Fig. 2A,
approximately, 13% of cells could be isolated as SP by the
Hoechst dye efflux method. Stemness of isolated SP cells was
proven by their specific overexpression of SOX2, OCT4, NANOG,
ABCB1 and ABCG2 genes. Significantly higher expression levels of
WNT1, WNT2, NOTCH1 and c-MYC were detected in SP cells
than those observed in NSP cells at both mRNA (Fig. 2B,
Fig. 2C) and protein levels (Fig. 2D), suggesting the molecular
mechanism underlying the high tumorigenic property of CSCs.
SOX2 Regulates the Expression of Oncogenes in A549
and H460 Cells
Since SOX2 is an important transcriptional factor that maintains
the function of CSCs, we hypothesized that SOX2 might regulate
the transcription of certain oncogenes in tumor cells. To test this
contention, A549 cells were established with stable expression of
doxycycline (Dox) inducible shRNA targeting SOX2 (A549-
H1tetO-shRNA-SOX2). The inducible knockdown of SOX2
was confirmed by Western blotting after 4 days’ incubation of
A549 cells with Dox, and 70% silencing efficiency of shRNA was
demonstrated in the expression of SOX2 gene (Fig. 3A). At the
same time, significant reduced percentage of SP in A549 cells with
SOX2 gene silencing was revealed (Fig. 3B and 3C), demon-
strating the important function of SOX2 in maintaining the CSC
properties of A549 cells. In addition, this finding also supported
the contribution of SOX2 to the tumorigenesis capacity of lung
cancer cells since it was well established that the SP has higher
tumorigenesis property than NSP in various types of lung cancer
cells [16]. By using real time RT-PCR and Western blotting,
significant reduced expressions of WNT1, NOTCH1 and c-MYC at
both mRNA and protein levels were shown in A549 cells with
SOX2 down-regulation (Fig. 3D and 3E). An interesting
phenomenon observed was that although mRNA expression of
WNT2 was slightly elevated upon silencing of SOX2, its protein
expression level decreased, indicating a translational inhibition of
WNT2 in A549 cells with SOX2 silencing. The same regulatory
effects of SOX2 on the expression of WNT1, WNT2, NOTCH1
and c-MYC were also observed in the human large cell lung
carcinoma cell line H460 with SOX2 silencing (Fig. 3E).This
finding indicates a universal regulatory mechanism of SOX2 on
the oncogene network of both human lung cell lines. These
findings support the notion that SOX2 may regulate the
transcription of key oncogenes in lung cancer to promote
tumorigenesis.
or without down-regulation of SOX2, n=3. E. Protein expression levels of WNT1, WNT2, NOTCH1 and c-MYC genes were detected in A549 and H460
cells with SOX2 silencing by Western blotting.
doi:10.1371/journal.pone.0036326.g003
SOX2 in Lung Cancer
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36326Figure 4. Silencing of SOX2 inhibits tumorigenesis and regulates expression of oncogenes in vivo. A. A549 cells were injected via the tail
vein into NOD/SCID mice and the bioluminescence images of xenografted tumor were taken at the times indicated. B. Bioluminescence intensity was
measured and plotted, n=5. C. HE staining was used to detect xenografted tumors in lung tissues of xenografted NOD/SCID mice. D.
Immunohistochemistry staining of SOX2, c-MYC, NOTCH1 and WNT1 (all shown in brown color) from lung tissues of xenografted NOD/SCID mice in
situ. E. Immunofluorescence of WNT2 (green) in xenografted murine lung tissues. All microscopy images were recorded under a 406objective. The
figures in C, D and E represent 1 of 5 experiments. The tumor regions in C, D and E were all circulated by dash lines.
doi:10.1371/journal.pone.0036326.g004
SOX2 in Lung Cancer
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36326Figure 5. Cluster image of the other target cancer genes of SOX2. Standardized TPM (transcripts per million clean tags) values were applied
to compare the other target cancer genes expression levels between A549 cells with SOX2 silencing (shRNA-SOX2) and their control (shRNA-Con). The
transcription of each gene is represented by a square with a color that codes for the values of Lg TPM. Specifically, bright green represents low
expression, bright red represents strong expression. The target genes whose transcriptions are up-regulated with the silencing of SOX2 were
presented in A and those down-regulated genes were presented in B.
doi:10.1371/journal.pone.0036326.g005
SOX2 in Lung Cancer
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Lung Cancer Cells in Xenografted NOD/SCID Mice
Following the identification of SOX2’s function on tumorigen-
esis and its regulatory effect on expression of oncogenes in human
lung cancer cells, we next explored its function in vivo. For this
purpose, A549-FL/H1tetO-shRNA-SOX2 and control cells were
inoculated into the NOD/SCID mice by tail vein injection. The
presence of A549-FL cells was monitored by noninvasive
bioluminescence imaging. The mice xenografted with A549-FL/
H1tetO-shRNA-SOX2 and A549-FL/H1tetO-shRNA-Con cells
were fed with Dox through drinking water from the first day after
inoculation to induce expression of shRNA. As observed in Fig. 4A
and 4B, same amount of bioluminescence signals could be
detected in mice 1 day after injection, indicating that the same
number of lung tumor cells became trapped in lung capillaries in
both experimental groups. Subsequent decrease in biolumines-
cence signals was detected in the 7 following days due to a failing
in survival of xenografted lung cancer cells [41]. Progressively
increasing signals could be observed in mice xenografted with
A549-FL/H1tetO-shRNA-Con cells after 14 days of treatment,
indicating that these cells had succeeded in homing and
proliferating. Twenty-one days after tumor cell challenge, 5 of 5
A549-FL/H1tetO-shRNA-Con xenografted mice developed tu-
mor, but only 2 of 5 A549-FL/H1tetO-shRNA-SOX2 xenograft-
ed mice developed tumor 42 days after initial tumor cell challenge.
Xenografted lung tumors in NOD/SCID mice were confirmed by
hematoxylin and eosin (HE) stainings as shown in Fig. 4C. The
protein expression levels of SOX2 and oncogenes in murine lung
tissues were assayed by immunohistochemistry or immunofluores-
cence methods. We found a reduced tumorigenesis potential of
A549 cells in vivo as well as a significantly attenuated expression of
WNT1, WNT2, NOTCH1 and c-MYC after silencing of the
SOX2 gene (Fig. 4D and Fig. 4E). Taken together, these results
supported the tumorigenic property of SOX2 and its regulatory
effect on oncogenes in vivo.
SOX2 Regulates the Transcriptional Network of
Oncogenes
Having identified the function of SOX2 in the tumorigenesis
property of lung cancer cells and its target oncogenes, we then
tested all the other targeted genes by RNA-Seq and found 246
cancer genes. Among them, 74 genes (30%) were up-regulated
(Fig. 5A) and 172 genes (70%) were down-regulated (Fig. 5B)i n
A549 cells with SOX2 silencing. We noticed the transcription levels
of NOTCH3 and WNT 7B are significantly reduced, revealing the
comprehensive effects of SOX2 on the transcription of WNT and
NOTCH gene families. In addition, the mRNA expression levels of
well-established oncogenes such as KLF4, EGFR, BCL10, JUN,
YAP1 and JAK1 et al. were significantly reduced when compared
with control cells, but the transcriptions of EGF, RHOC et al. were
greatly increased, demonstrating the complicated molecular
mechanism in the tumorigenesis process of SOX2. In addition,
our RNA-Seq result revealed 840 differentially expressed genes
(DEG) with pathway annotation after SOX2 silencing in A549
cells. Through enrichment analysis of SOX2 target genes in the
cell signaling pathway database of Kyoto Encyclopedia of Genes
and Genomes (KEGG), we found the pathway in cancer is one of
the most significantly enriched ones (Table 3 and Fig. S1). This
result further supports the important function of SOX2 in
development of tumor.
Discussion
In this study, we used immunohistochemistry to systemically
analyze the expression of SOX2 in various types of lung cancers
and found that SOX2 is predominantly overexpressed in
adenocarcinoma, SCC, large cell carcinomas and SCLC tissues,
indicating that SOX2 can be used as a universal marker for the
diagnosis of human lung cancer. Here we also present evidence
indicating that SOX2 plays an important role in carcinogenesis of
lung cancer.
Since the concept of CSC has been established, many studies
supported this concept by demonstrating that CSCs or CSCs like
cells are highly tumorigenic [16]; however, few studies have been
performed to investigate the molecular mechanism of this
phenomenon. Here we demonstrated a higher expression of
SOX2 and oncogenes- NOTCH1, WNT1, WNT2 as well as c-MYC
in SP cells than those in NSP cells, thus supporting a possible
contribution of these oncogenes to the stemness property of CSCs.
Recent studies have revealed the complicated interaction
between SOX2 and WNT signaling pathway. For example, it
was reported that SOX2 antagonizes the WNT signaling to inhibit
the differentiation of adult stem cells (ASCs) [42] and osteoblast
lineage [43] and enhance the tumorigenesis and self renewal
property of osteosarcomas [44] by promoting the transcription of
negative regulator of WNT signaling, such as DKK1, APC and
GSK3b. SOX2 was also reported to synergistically interacted with
b-catenin, the downstream molecule of the WNT signal pathway,
to regulate the transcription of a target gene to promote cell
proliferation and tumorigenesis of human breast cancer [23].
However, as an important stem cell gene, the underlying
molecular mechanism of SOX2’s function in tumorigenesis is
comprehensive and still needs to be intensively investigated. In this
regard, our results demonstrated that silencing of SOX2 signifi-
cantly reduces the protein expression level of oncogenes-WNT1,
WNT2, c-MYC and NOTCH1 in human lung cancer and further
revealed other target cancer genes of SOX2. It is thus possible that
SOX2 can cooperate with these important oncogenes to promote
tumor occurrence. Recent study showed down-regulation of SOX2
gene inhibits proliferation and induces apoptosis in tumor cells
[15,45,46], we observed the same phenomenon in human lung
cancer cell lines (data not shown), those may also be important
factors that finally lead to the suppressed tumor growth in A549
cells; however, this study focused on the transcriptional changes of
oncogenes and did not address other mechanisms.
Bioluminescence imaging is a novel diagnostic system that
provides an easy and noninvasive visualization of the size and
location of tumor cells in xenografted animals. Two types of
models are usually applied to explore tumorigenicity of lung
cancer cells: one is the intravenous metastasis model and the other
is the subcutaneous flank tumor model [47,48]. The first model
was used in our study to observe SOX2’s function in the
tumorigenesis of lung cancer in vivo, which reflected the whole
process of homing and proliferation of tumor cells in lung. It was
interesting to find that after 42 days of tumor cell inoculation, lung
tumors could be detected in 2 of the 5 A549-FL/H1tetO-shRNA-
SOX2 xenografted mice. From the immunohistochemistry stain of
tumor tissues, the possibility that the tumor formed from
‘‘escaper’’ cells that not responsive to shRNA-SOX2 could be
excluded, since the stain intensity of SOX2 was obviously
decreased in the shRNA-SOX2 group. It is thus possible that
the transcription of other oncogenes may not be affected or could
even be unregulated by SOX2 and this may be the key reason
leading to tumor occurrence in NOD/SCID mice. This possibility
was verified by RNA-Seq screening of the targeted cancer genes of
SOX2 in Lung Cancer
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after SOX2 gene silencing. Discovery of these genes’ function in the
occurrence of tumor after SOX2 down-regulation and use of
combined therapies targeting them and the SOX2 gene may
improve the outcome of lung tumor therapy.
In summary, this study broadens our understanding of the
molecular mechanism of tumorigenesis of both CSCs and SOX2.
Our study supports the notion that silencing of the SOX2 gene is
an effective strategy for human lung cancer therapy.
Supporting Information
Figure S1 Pathway in cancer, one of the most signifi-
cantly enriched pathways of SOX2 targets from KEGG
cell signaling pathway database. The frame showed the
SOX2 target that was down-regulated (green) or up-regulated (red)
upon SOX2 silencing.
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